LH Paul R. Kirchgraber sold LABORATORY CORP OF AMERICA HOLDINGS shares — SEC Form 4SELLLABORATORY CORP OF AMERICA HOLDINGS

Paul R. Kirchgraber, CEO, Covance Drug Development at LABORATORY CORP OF AMERICA HOLDINGS (LH), sold 4,300 shares at $216.91 ($933K) on 2023-05-19, disclosed to the SEC on 2023-05-23.

SEC EDGAR Filing

0001127602-23-016525

View on SEC EDGAR

Trade context

Open-market sale of $933k LH by CEO, Covance Drug Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.

Modest57/100

Nothing distinguishes this filing.

Opportunistic SellExercise & Sell

Trade Context

•Decreased holdings by 25%
•2nd largest sale, out of 4
•Stock down -15% in previous 3 months

Filing Info

Filed2023-05-23

Traded2023-05-19

Accession0001127602-23-016525

SourceSEC EDGAR (Historical)

Insider

NamePaul R. Kirchgraber

TitleCEO, Covance Drug Development

PIT GradeInsiderUnrated

View Company View Insider

Related Trades by This Insider

Ticker	Type	Filed	Value	7d Stock	Filing
LH	SELL	2023-02-23	$2.0M	—	Filing →
LH	SELL	2021-05-10	$691K	—

Get an email when an insider at LH files

Free account. Follow LH and up to 10 more companies.

Follow LH for free

LH Paul R. Kirchgraber sold LABORATORY CORP OF AMERICA HOLDINGS shares — SEC Form 4SELLLABORATORY CORP OF AMERICA HOLDINGS

Trade Context

Filing Info

Insider

Related Trades by This Insider

Trade Details

Outcomes